Anti-Nuclear Ab by IFA (RDL): What Positive, Negative, and Abnormal Results Mean

Sample type: Serum

Other names: Anti-Nuclear Ab by IFA (RDL), Anti-Nuclear Ab by IFA RDL, Antinuclear Ab by IFA (RDL), Antinuclear Ab by IFA RDL, ANA by IFA (RDL), ANA IFA RDL, Anti-Nuclear AB by IFA, Antinuclear Antibodies IFA, Antinuclear Antibodies by IFA, ANA Screen IFA, ANA Screen by IFA, ANA IFA Screen, ANA IFA, ANA IFA Positive, ANA IFA Positive Abnormal, ANA IFA Negative, ANA by IFA RFX, ANA by IFA RFX Titer/Pattern, ANA Screen IFA W/Refl Titer and Pattern, ANA with Reflex to IFA, ANA with Reflex, ANA IFA Screen W/Refl to Titer and Pattern, Antinuclear Ab by IFA Positive, Antinuclear Antibodies IFA Positive, Antinuclear Antibodies IFA Negative, Anti-Nuclear Ab by IFA (RDL) Positive, Anti-Nuclear Ab by IFA (RDL) Positive Abnormal, Anti-Nuclear Ab by IFA (RDL) Abnormal, WarningAbnormalAnti-Nuclear Ab by IFA (RDL), WarningAbnormal Anti-Nuclear Ab by IFA (RDL), AbnormalAnti-Nuclear Ab by IFA (RDL), Abnormal Anti-Nuclear Ab by IFA (RDL), Anti-Nuclear Ab by IFA (RDL) Positive Speckled Pattern, Anti-Nuclear Ab by IFA (RDL) Positive Homogeneous Pattern, Anti-Nuclear Ab by IFA (RDL) Speckled Pattern, Anti-Nuclear Ab by IFA (RDL) Homogeneous Pattern, ANA 12 Plus Profile, ANA 12 Plus Profile (RDL), ANA 12 Plus Profile RDL, ANA Profile 12 (RDL), ANA Profile 12 RDL, ANA 12 Profile, ANA 12 Plus, ANA 12 Plus Profile Positive, ANA 12 Plus Profile Do All RDL, ANA 12 Plus Profile Do All (RDL), ANA Comprehensive Plus Profile, ANA Comprehensive Profile, ANA Plus Profile, ANA Plus 12 Profile, ANA Plus 12 Interpretation, RDL Blood Test, RDL Test, RDL Lab Test, RDL Lab, RDL Medical, RDL Meaning Medical, What is RDL in Blood Test, RDL Lab Meaning, RDL Result, RDL Positive, RDL Positive Abnormal, Anti-Nuclear Ab by IFA (RDL) High, ANA Screen IFA Positive, ANA Screen IFA Positive Abnormal, ANA Screen IFA Abnormal, ANA IFA Result, ANA Titer 1:40, ANA Titer 1:80, ANA Titer 1:160, ANA Titer 1:320, ANA Titer 1:640, ANA Titer 1:1280, ANA Speckled Pattern, ANA Homogeneous Pattern, ANA Nucleolar Pattern, ANA Centromere Pattern, Speckled ANA Pattern, Homogeneous ANA Pattern, ANA Titer 1:40 Speckled, Nuclear Ab by IFA (RDL), Nuclear Ab, Nuclear Ab Positive, Antinuclear Ab Screen, Anti-Nuclear Antibody by IFA, ANA Antinuclear Antibody, Antinuclear Antibody IFA Positive, ANA IFA Test, ANA IFA Method, Anti-Nuclear Ab by IFA (RDL) 02, F Anti-Nuclear Ab by IFA (RDL), ANA IFA LC Positive, ANA By IFA RFX Titer/Pattern Positive, ANA By IFA RFX Titer/Pattern Negative, ANA Screen IFA W/Refl Titer and Pattern IFA, Anti-Nuclear Ab IFA, Antinuclear AB IFA, ANA Negative Lupus, ANA Positive Lupus, Anti Nuclear Ab by IFA Positive Meaning, DFS70 Antibody with Positive ANA, Positive ANA All Specific Antibodies Negative, ANA Screen IFA W/Refl ENA and dsDNA

Negative

A negative Anti-Nuclear Ab by IFA (RDL) result means no antinuclear antibodies were detected above the reporting threshold. This is the expected normal result and is highly reassuring in the context of suspected autoimmune disease. The ANA by IFA test has high sensitivity for most ANA-associated rheumatic conditions — approximately 95% of lupus cases have a positive ANA — meaning a negative result makes these conditions unlikely. In the ANA 12 Plus Profile, anti-Ro/SS-A testing is still performed even when ANA is negative, because a small percentage of Ro-antibody-positive cases may be negative on standard ANA IFA screening. In a patient with persistent symptoms strongly suggestive of a connective tissue disease despite a negative ANA, clinical evaluation and targeted specific antibody testing may still be appropriate.

Positive

A positive Anti-Nuclear Ab by IFA (RDL) result means antinuclear antibodies were detected in the blood above the reporting threshold. If your HealthMatters dashboard shows "WarningAbnormalAnti-Nuclear Ab by IFA (RDL)," the clinically meaningful part is "Positive" — "WarningAbnormal" is a dashboard alert flag and "(RDL)" identifies the LabCorp/RDL testing platform; neither indicates the result is urgent or severe. A positive ANA finding indicates that the immune system is producing antibodies targeting structures within cell nuclei. This is a common finding — data from Tan et al. shows ANA positivity in approximately 31.7% of healthy adults at 1:40 dilution and 13.3% at 1:80. A positive ANA alone does not diagnose any specific autoimmune condition. The clinical significance depends on the titer, the fluorescence pattern, the presence and nature of any symptoms, and the results of specific reflex antibody tests such as anti-dsDNA, anti-Smith, anti-SSA/SSB, and complement levels. Low-titer results (1:40 or 1:80) in asymptomatic individuals are frequently incidental findings that do not require immediate intervention. Higher-titer results (1:160 and above), particularly with symptoms such as persistent joint swelling, photosensitive rash, dry eyes and mouth, or Raynaud's phenomenon, warrant rheumatology evaluation.

QUICK ANSWER

The Anti-Nuclear Ab by IFA (RDL) is a blood test that detects antinuclear antibodies — immune proteins that target the body's own cell nuclei. It is used as a screening test for autoimmune conditions, particularly connective tissue diseases.

Two things to know immediately:

  1. "RDL" is not a result — it identifies LabCorp's RDL rheumatology testing platform. It appears in the test name because this test is processed through that platform. It has no clinical meaning.
  2. A positive result does not mean you have lupus — low-titer positive ANA is common in healthy individuals. Titer, pattern, symptoms, and specific antibody results all determine clinical significance.
Result on your report What it means
Negative No ANA detected above the reporting threshold — expected result for most people
Positive ANA detected — requires interpretation of titer and pattern; does not diagnose any specific disease by itself
Positive Abnormal Same as Positive — "Abnormal" is the lab flag indicating the result is outside the reference interval (Negative)
WarningAbnormal The HealthMatters dashboard label for a Positive ANA result — reflects the alert classification, not medical urgency

Common questions at a glance:

Question Short answer
What does "RDL" mean in my blood test? LabCorp's RDL rheumatology testing platform — a lab identifier, not a result type
What does positive ANA mean? Antinuclear antibodies were detected; titer, pattern, and symptoms determine significance
Does a positive ANA mean I have lupus? Not by itself — positive ANA is common in healthy people; lupus requires multiple criteria beyond a positive ANA
What is a normal ANA result? Negative — no antinuclear antibodies detected above the reporting threshold
What does "WarningAbnormal" mean on HealthMatters? The ANA was positive (above reference interval); "Warning" is the dashboard alert level, not a measure of medical urgency

WHAT IS "RDL" IN MY BLOOD TEST? — THE MOST IMPORTANT DECODER

The "(RDL)" in "Anti-Nuclear Ab by IFA (RDL)" does not describe your result. It is a laboratory platform identifier.

RDL refers to LabCorp's RDL rheumatology testing platform — a specialized testing infrastructure that LabCorp built on the foundation of RDL Reference Laboratory. When LabCorp processes ANA testing by indirect fluorescent antibody (IFA) method, it routes this testing through the RDL platform. LabCorp appends the platform identifier to the test name, which is why you see "(RDL)" in the name on your report and in HealthMatters.

What "(RDL)" means What "(RDL)" does NOT mean
LabCorp's RDL rheumatology testing platform A type of result (it is not a result category)
Identifies the testing platform used for this assay A severity level or warning
Appears on LabCorp reports for tests processed through the RDL platform Anything about whether your result is positive or negative

Why does this matter? Because many users search "what is RDL in blood test" or "RDL positive" believing RDL is a clinical finding. It is not. Your clinical result is the Positive or Negative designation — RDL only tells you which platform analyzed the sample.

Other LabCorp tests that use similar platform identifiers include tests labeled "(RDL)" for rheumatology assays or "(LC)" for tests performed on LabCorp's own platform. The identifier in parentheses is always the performing lab or platform, never the result.


WHAT DOES "WARNINGABNORMAL" MEAN ON HEALTHMATTERS?

If your HealthMatters dashboard shows "WarningAbnormalAnti-Nuclear Ab by IFA (RDL)" or "Abnormal Anti-Nuclear Ab by IFA (RDL)", this means:

  • Your ANA result was Positive (above the reference interval, which is Negative)
  • The HealthMatters system flagged it with a Warning alert level
  • The word "Warning" reflects the alert classification in the dashboard — it does not mean the result is medically dangerous or requires emergency action

Which part of "WarningAbnormalAnti-Nuclear Ab by IFA (RDL) Positive" is my actual result?

The actual result is Positive. Here is what each component means:

  • Warning = HealthMatters alert level for an above-range result
  • Abnormal = the result is outside the reference interval (Negative)
  • Anti-Nuclear Ab by IFA = the test name
  • (RDL) = the LabCorp/RDL testing platform identifier
  • Positive = your clinical result

The clinical interpretation depends on the ANA titer, pattern, symptoms, and follow-up antibody results — not on the dashboard label.


WHAT DOES A POSITIVE ANA MEAN?

A positive Anti-Nuclear Ab by IFA result means antinuclear antibodies were detected in your blood above the reporting threshold. ANA are proteins produced by the immune system that target structures within the nucleus of cells.

A positive ANA alone does not diagnose any specific disease. It is a screening test. The clinical significance of a positive ANA depends on:

Factor Why it matters
Titer level Low titers (1:40, 1:80) are common in healthy individuals; higher titers are more likely to be clinically significant
Fluorescence pattern Different patterns suggest different possible underlying antibodies and associated conditions
Symptoms A positive ANA with no symptoms has different significance than a positive ANA with joint pain, rash, and fatigue
Specific antibody results Tests such as anti-dsDNA, anti-Smith, anti-SSA/SSB are more diagnostically specific than ANA alone
Clinical context Age, sex, medications, and family history all affect interpretation

How common is a positive ANA in healthy people? In a landmark study by Tan et al., ANA was detectable in healthy individuals at these rates: 31.7% at 1:40, 13.3% at 1:80, 5.0% at 1:160, and 3.3% at 1:320. This is why titer matters — a 1:40 positive is found in nearly one in three healthy adults.

What symptoms make a positive ANA more meaningful? Not all symptoms are equally specific. Symptoms that make a positive ANA clinically more significant include: persistent inflammatory joint swelling, photosensitive rash (especially butterfly/malar rash), mouth ulcers, Raynaud's phenomenon, unexplained low blood counts, protein or blood in the urine, pleuritic chest pain, dry eyes and dry mouth, skin thickening, or recurrent unexplained fevers. Fatigue alone is common and nonspecific for autoimmune disease.


YOUR ANA TITER — WHAT DOES YOUR NUMBER MEAN?

When an ANA is positive, the lab reports a titer — a dilution ratio reflecting the concentration of antinuclear antibodies. The higher the titer, the more concentrated the antibodies. LabCorp reports ANA starting at 1:40 or 1:80 depending on the test option ordered.

ANA titer Prevalence in healthy adults (Tan et al.) Interpretation
Negative — No ANA detected above reporting threshold — standard negative result
1:40 ~31.7% of healthy adults Very low positive; extremely common in healthy people; often incidental; low clinical significance in isolation
1:80 ~13.3% of healthy adults Low positive; common in healthy people; used as the entry threshold in 2019 EULAR/ACR SLE classification criteria, but not diagnostic by itself
1:160 ~5.0% of healthy adults More clinically meaningful; found in fewer healthy individuals; warrants evaluation of pattern and specific antibody results
1:320 ~3.3% of healthy adults Higher positive; less common in healthy people; more concerning when accompanied by symptoms
1:640 Much less common High positive — clinical significance depends strongly on symptoms and specific antibody results
1:1280 and above Uncommon in healthy adults Very high positive — more likely to be clinically significant, especially with symptoms; rheumatology evaluation appropriate; note that titer alone does not prove active disease

What does 1:40 mean? A titer of 1:40 means antibodies were detectable when serum was diluted 40-fold. This is the lowest reportable positive threshold on many assays and is found in nearly one in three healthy adults. A 1:40 ANA in an asymptomatic person is usually not clinically significant.

What does 1:80 mean? 1:80 is important because it is the entry threshold used in the 2019 EULAR/ACR SLE classification criteria — meaning 1:80 on HEp-2 IFA is required before the classification system is even applied. However, 1:80 is found in approximately 13% of healthy adults and is not diagnostic of lupus or any autoimmune disease on its own.

What does 1:160 and above mean? Titers of 1:160 and higher are present in fewer healthy individuals (~5% at 1:160) and carry increasing clinical significance when accompanied by relevant symptoms or specific antibody abnormalities.


ANA FLUORESCENCE PATTERN — WHAT YOUR PATTERN MEANS

A positive ANA by IFA also reports a fluorescence pattern — the appearance of ANA staining on HEp-2 cells under a fluorescent microscope. Different patterns suggest possible underlying antibodies and associated conditions.

Important: ANA patterns are general clues, not diagnoses. LabCorp specifically notes that ANA patterns on HEp-2 slides provide only general clues and, except for centromere pattern, are not reliably correlated with specific antibodies. Specific antibody testing is required to identify which antibody is actually present.

Pattern Possible associated antibodies / follow-up tests Conditions to consider
Homogeneous (Diffuse) Anti-dsDNA, anti-histone, anti-chromatin/nucleosome Systemic lupus erythematosus (SLE), drug-induced lupus
Speckled Anti-SSA/Ro, anti-SSB/La, anti-Smith, anti-U1 RNP, other ENA antibodies Sjögren's syndrome, SLE, mixed connective tissue disease (MCTD), overlap syndromes
Nucleolar Anti-Scl-70 (topoisomerase I), anti-RNA polymerase III, anti-PM-Scl Systemic sclerosis (scleroderma) spectrum
Centromere Anti-centromere antibody — centromere pattern is more reliably correlated with anti-centromere antibodies than other patterns Limited systemic sclerosis (CREST syndrome)
Nuclear dots Anti-Sp100, anti-PML Primary biliary cholangitis, sometimes incidental
Cytoplasmic Anti-Jo-1, anti-mitochondrial Polymyositis/dermatomyositis, primary biliary cholangitis

What does "speckled pattern" mean? The speckled pattern is the most common positive ANA pattern. It indicates antibodies targeting proteins distributed throughout the nucleus. Multiple specific antibodies can produce a speckled pattern — including anti-SSA/Ro (Sjögren's), anti-SSB/La (Sjögren's), anti-Smith (lupus), and anti-U1 RNP (MCTD). Specific antibody testing is required to determine which one is present. A speckled pattern at low titer (1:40–1:80) with no symptoms is common and usually not clinically significant.

What does "homogeneous pattern" mean? The homogeneous (diffuse) pattern shows uniform nuclear staining. It is classically associated with SLE (anti-dsDNA) and drug-induced lupus (anti-histone), but is also seen in healthy individuals at low titers. A homogeneous pattern with high titer and symptoms would typically prompt anti-dsDNA and complement level (C3/C4) testing.


THE ANA 12 PLUS PROFILE (RDL) — WHAT IS THIS PANEL?

If your HealthMatters dashboard shows "ANA 12 Plus Profile (RDL)" or "ANA 12 Plus Profile Do All (RDL)", this refers to LabCorp test code 520180 — a reflexive autoimmune panel.

How the ANA 12 Plus Profile works:

  • The panel starts with the ANA by IFA screen
  • If ANA is positive, LabCorp automatically performs the full reflex profile of specific antibody and complement tests
  • If ANA is negative, Anti-Ro/SS-A testing is still performed — because a small percentage of cases with Ro antibodies may have a negative or low ANA by IFA

Components of the ANA 12 Plus Profile (LabCorp 520180):

Component Why it matters
Anti-Nuclear Ab by IFA (RDL) ANA screen — the starting test; includes titer and pattern
Anti-dsDNA Ab (by Farr method) Highly specific for SLE; correlates with disease activity
Anti-Smith (Sm) Ab Highly specific for SLE; diagnostic when positive
Anti-U1 RNP Ab Mixed connective tissue disease and overlap syndromes
Anti-Ro/SS-A Ab Sjögren's syndrome, neonatal lupus, SLE; also performed when ANA is negative
Anti-La/SS-B Ab Sjögren's syndrome, SLE context
Anti-Scl-70 (Topoisomerase I) Ab Diffuse systemic sclerosis (scleroderma)
Anti-Centromere Ab Limited systemic sclerosis (CREST syndrome)
Anti-Chromatin Ab, IgG SLE, drug-induced lupus context
Anti-TPO Ab Autoimmune thyroid disease — may coexist with connective tissue disease
C3 Complement Lupus disease activity; reduced by immune complex consumption
C4 Complement Lupus disease activity; reduced by immune complex consumption
Rheumatoid Factor by Turbidimetry Rheumatoid arthritis and overlap context
Anti-CCP Ab Rheumatoid arthritis specificity
Anticardiolipin IgG, IgA, IgM Antiphospholipid syndrome context

"Do All" vs. reflexive: "ANA 12 Plus Profile Do All (RDL)" means all components were ordered simultaneously regardless of the ANA screening result, rather than waiting for a positive ANA to trigger the reflex tests. This is done when comprehensive autoimmune screening is wanted immediately.


HOW THE ANA REFLEX CASCADE WORKS

A positive ANA by IFA typically triggers reflex testing — additional specific antibody tests ordered automatically when the screening result is positive. This is why a single blood draw may produce multiple additional results.

ANA result What typically happens next
Negative Anti-Ro/SS-A still performed (in ANA 12 Plus Profile); otherwise no reflex
Positive at 1:40–1:80 Reflex antibody panel triggered depending on the ordering panel
Positive at 1:80 or above Full reflex antibody panel typically triggered
Positive + Speckled pattern Anti-SSA/Ro, anti-SSB/La, anti-Smith, anti-RNP most relevant follow-up
Positive + Homogeneous pattern Anti-dsDNA, anti-histone, anti-chromatin most relevant follow-up
Positive + Nucleolar pattern Anti-Scl-70, anti-RNA polymerase III, anti-PM-Scl most relevant follow-up
Positive + Centromere pattern Anti-centromere antibody; limited scleroderma evaluation

WHAT DOES A NEGATIVE ANA MEAN?

A negative Anti-Nuclear Ab by IFA result means no antinuclear antibodies were detected above the reporting threshold. This is the expected, normal result and is highly reassuring in most clinical contexts. The ANA by IFA test has high sensitivity for most ANA-associated rheumatic conditions — particularly lupus, where approximately 95% of cases have a positive ANA.

A negative ANA makes most ANA-associated autoimmune diseases unlikely, but rare exceptions exist:

Situation Notes
Negative ANA with lupus symptoms Rare (~5% of lupus cases); anti-dsDNA or anti-Smith may still be positive
Negative ANA on the ANA 12 Plus Profile Anti-Ro/SS-A is still performed because a small percentage of Ro-positive cases have negative ANA by IFA
Negative ANA with scleroderma features Anti-Scl-70 can occasionally be present with low or negative ANA
Negative ANA on immunosuppressive therapy Medications may suppress ANA to undetectable levels

WHAT IF MY ANA IS POSITIVE BUT ALL SPECIFIC ANTIBODIES ARE NEGATIVE?

This is a very common and often anxiety-provoking situation. A positive ANA — especially at low titer — with negative specific antibody tests (negative anti-dsDNA, anti-Smith, anti-SSA/SSB, anti-Scl-70, etc.) has low predictive value for most autoimmune rheumatic diseases.

Several things can explain this pattern:

Explanation What it means
Low-titer incidental positive 1:40 or 1:80 ANA with negative specific antibodies in an asymptomatic person is very likely incidental and not clinically significant
Anti-DFS70 pattern Anti-DFS70 (dense fine speckled 70) antibody is associated with a characteristic ANA pattern and — when present in isolation without other specific antibodies — is associated with a lower likelihood of systemic autoimmune rheumatic disease. If suspected, specific DFS70 antibody testing can be ordered
Antibodies not included in the panel Some autoimmune conditions involve antibodies not routinely tested (e.g., anti-MDA5, anti-TIF1-gamma in myositis); specialist evaluation may be needed
Early or evolving disease Specific antibodies may develop later; clinical follow-up is warranted if symptoms progress

A positive ANA with all negative specific antibodies and no symptoms is not a diagnosis of any autoimmune disease and usually does not require immediate action beyond clinical correlation.


MOST COMMON CLINICAL SCENARIOS

Pattern Most likely interpretation Recommended next step
Negative ANA + no symptoms Expected result — no autoimmune disease suggested Routine monitoring
Positive ANA 1:40 + no symptoms Common incidental finding; found in ~32% of healthy adults Clinical correlation; repeat if symptoms develop
Positive ANA 1:80 + no symptoms Low positive — common; 1:80 is EULAR/ACR SLE entry threshold but not diagnostic Discuss with doctor; no action usually needed without symptoms
Positive ANA 1:160+ + joint swelling, rash, or fatigue with objective findings Clinically significant positive with specific symptoms Reflex antibody panel; rheumatology evaluation
Positive ANA + speckled pattern + dry eyes and dry mouth Sjögren's pattern Anti-SSA/Ro, anti-SSB/La testing; rheumatology referral
Positive ANA + homogeneous pattern + butterfly rash Lupus pattern Anti-dsDNA, complement levels (C3/C4), anti-Smith
Positive ANA + centromere pattern + Raynaud's CREST/limited scleroderma pattern Rheumatology evaluation; confirm with anti-centromere antibody
Positive ANA + nucleolar pattern + skin thickening Diffuse scleroderma pattern Anti-Scl-70, anti-RNA polymerase III; rheumatology
Positive ANA + normal ESR/CRP + no specific symptoms Often incidental, especially at low titer Clinical correlation; avoid overdiagnosis
Positive ANA + low C3/C4 + positive dsDNA Lupus pattern, especially with symptoms Prompt rheumatology evaluation
Positive ANA + all specific antibodies negative Common; low predictive value especially at low titer Reassure if asymptomatic; consider DFS70 testing; follow if symptoms develop
Positive ANA + thyroid antibodies (anti-TPO) positive Autoimmune thyroid disease may coexist Thyroid evaluation; interpret ANA separately for rheumatic disease
Positive ANA + medications (procainamide, hydralazine, minocycline) Drug-induced lupus-like syndrome possible Discuss medication history with doctor; anti-histone antibody
Positive ANA 12 Plus Profile with multiple specific antibodies positive Significant autoimmune panel Rheumatology evaluation required

WHEN SHOULD I WORRY ABOUT A POSITIVE ANA?

Situation Concern level Recommended action
Positive ANA 1:40 or 1:80 + no symptoms + no specific antibodies Low Discuss with doctor; likely incidental; recheck if symptoms develop
Positive ANA + nonspecific symptoms only (fatigue, mild aches) + low titer Low-Moderate Discuss with doctor; evaluate common non-autoimmune causes too
Positive ANA + specific autoimmune features (joint swelling, rash, dry eyes) Moderate Rheumatology referral usually appropriate
Positive ANA 1:160+ + objective symptoms or signs Moderate-High Reflex antibody panel + rheumatology evaluation
Positive ANA + positive dsDNA/Sm + low complements + kidney findings High Prompt rheumatology evaluation; possible lupus
Positive ANA + positive anti-Scl-70 or anti-centromere Moderate-High Rheumatology; evaluate for scleroderma spectrum
Positive ANA + positive anticardiolipin or anti-U1 RNP Moderate Rheumatology evaluation for antiphospholipid syndrome or MCTD
Anti-Nuclear Ab by IFA (RDL)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Anti-Nuclear Ab by IFA (RDL) — 10,000+ markers explained
One Anti-Nuclear Ab by IFA (RDL) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time

Frequently Asked Questions

What does "RDL" mean in my blood test result?
RDL refers to LabCorp's RDL rheumatology testing platform — a specialized testing infrastructure built on the foundation of RDL Reference Laboratory. When LabCorp processes ANA testing by indirect fluorescent antibody (IFA) method, it routes this testing through the RDL platform and appends the platform identifier to the test name. This is why you see "(RDL)" after the test name on your report and in HealthMatters. RDL is not a result category, not a type of positive or negative finding, and not a clinical designation. Your actual result is the Positive or Negative designation.
Which part of "WarningAbnormalAnti-Nuclear Ab by IFA (RDL) Positive" is my actual result?
The actual result is Positive. Breaking down the full string: "Anti-Nuclear Ab by IFA" is the test name; "(RDL)" identifies the LabCorp/RDL testing platform; "Abnormal" means the result is outside the reference interval (Negative); "Warning" is the HealthMatters alert level for an above-range result. The clinical interpretation depends on the ANA titer, fluorescence pattern, your symptoms, and any follow-up antibody results — not on the dashboard label itself.
What does "Anti-Nuclear Ab by IFA (RDL) Positive" mean?
It means antinuclear antibodies were detected in your blood above the reporting threshold. The test uses indirect fluorescent antibody (IFA) method, where your serum is applied to HEp-2 cells on a slide and antibody binding is visualized under a fluorescent microscope. A positive result means ANA were found. The clinical significance depends on the titer level, the fluorescence pattern, whether you have symptoms of an autoimmune condition, and the results of any specific antibody reflex tests.
Does a positive ANA mean I have lupus?
Not necessarily — and in most cases, no. A positive ANA is common in lupus (approximately 95% of SLE cases are ANA-positive) and is used as an entry criterion in the 2019 EULAR/ACR classification system at a titer of 1:80 or above. However, a positive ANA is also found in approximately 31.7% of healthy adults at 1:40 and 13.3% at 1:80. Lupus is diagnosed using multiple criteria including specific symptoms, characteristic rashes, kidney involvement, specific antibodies (anti-dsDNA, anti-Smith), complement levels, and clinical evaluation by a rheumatologist. A positive ANA alone is not sufficient to diagnose lupus.
What does "WarningAbnormal" mean on my HealthMatters dashboard?
The "WarningAbnormal" prefix on your HealthMatters result means your ANA test came back Positive — which is above the reference interval (Negative). "Warning" is the dashboard's alert classification for this result category. It does not mean the result is medically dangerous or requires emergency action. The next step is to review the titer and pattern on your full lab report and discuss with your doctor, particularly if you have symptoms.
What does the ANA titer mean?
The titer is the dilution ratio at which your blood still shows detectable ANA. A titer of 1:40 means antibodies were detectable when serum was diluted 40-fold; 1:320 means still detectable at 320-fold dilution. Higher titers indicate more concentrated antibodies. Using data from Tan et al., approximately 31.7% of healthy adults are ANA-positive at 1:40, 13.3% at 1:80, 5.0% at 1:160, and 3.3% at 1:320. A titer of 1:160 and above in a symptomatic patient typically warrants rheumatology evaluation and specific antibody testing.
What does a speckled ANA pattern mean?
The speckled pattern is the most common positive ANA fluorescence pattern. Multiple specific antibodies can produce a speckled pattern, including anti-SSA/Ro (Sjögren's syndrome), anti-SSB/La (Sjögren's), anti-Smith (lupus), and anti-U1 RNP (mixed connective tissue disease). LabCorp notes that patterns other than centromere are not reliably correlated with specific antibodies — specific antibody testing is required to determine which antibody is responsible. A speckled pattern at low titer with no symptoms is common and usually not clinically significant.
What does a homogeneous ANA pattern mean?
The homogeneous (diffuse) pattern shows uniform staining across the nucleus. It is most classically associated with systemic lupus erythematosus through anti-dsDNA antibodies, and with drug-induced lupus through anti-histone antibodies. However, it is also seen in healthy individuals at low titers. A homogeneous pattern with high titer and symptoms typically prompts anti-dsDNA and complement level (C3/C4) testing.
What is the ANA 12 Plus Profile (RDL)?
The ANA 12 Plus Profile (RDL) is LabCorp test 520180 — a reflexive autoimmune panel that starts with the ANA by IFA screen and, if positive, automatically performs a comprehensive set of specific antibody and complement tests including anti-dsDNA, anti-Smith, anti-U1 RNP, anti-SSA/Ro, anti-SSB/La, anti-Scl-70, anti-centromere, anti-chromatin, anti-TPO, C3 and C4 complement, rheumatoid factor, anti-CCP, and anticardiolipin antibodies (IgG, IgA, IgM). If ANA is negative, anti-Ro/SS-A is still performed because a small percentage of cases with Ro antibodies may be ANA-negative.
What if my ANA is positive but all my specific antibodies are negative?
This is common and usually reassuring — particularly at low titer (1:40 or 1:80) with no autoimmune symptoms. A positive ANA screen with negative specific antibodies has low predictive value for most systemic autoimmune rheumatic diseases. One specific scenario worth knowing: when anti-DFS70 antibody is the cause of a positive ANA (producing a characteristic dense fine speckled pattern), it is associated with a lower likelihood of autoimmune rheumatic disease when found in isolation without other specific antibodies. If your ANA is positive with negative specific antibodies and you have no relevant symptoms, this finding usually requires clinical correlation rather than immediate further workup.
Should I repeat a positive ANA test?
Usually not immediately. ANA can remain positive for years without indicating active disease, and ANA titer does not reliably track disease activity in most conditions. Repeating ANA is most useful when the original result was borderline low-titer, symptoms have changed significantly, or the clinician needs to clarify an uncertain result. In established autoimmune disease, follow-up monitoring typically focuses on disease-specific markers (anti-dsDNA, complements, CBC, kidney function, urinalysis) rather than repeating the ANA screen itself.
Can a positive ANA go away or become negative?
Yes — particularly at low titers. A 1:40 or 1:80 ANA may revert to negative on repeat testing, especially if the initial positive was incidental, occurred during an acute illness or infection, or was related to a medication (stopping the medication often resolves the ANA). In established autoimmune disease, ANA levels may persist and fluctuate but often do not track disease activity closely.
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

  1. Range of antinuclear antibodies in "healthy" individuals
    Arthritis Rheum. · 1997 View source ↗
  2. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
    Arthritis Rheumatol. · 2019 View source ↗
  3. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
    Ann Rheum Dis. · 2014 View source ↗
  4. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases
    Arthritis Rheum. · 2011 View source ↗
Article Review Log
Last reviewed June 19, 2026
Originally published June 19, 2026
Reviewed by HealthMatters Editorial Team
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro